NCT05124795View on ClinicalTrials.gov

IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer

PHASE1TerminatedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

December 9, 2021

Primary Completion Date

May 31, 2023

Study Completion Date

May 31, 2023

Conditions

Metastatic Castration Resistant Prostate Cancer

Interventions

DRUG

IMU-935

IMU-935 capsules

Trial Locations (1)

SM2 5PT

Institute of Cancer Research, London

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Immunic AG

INDUSTRY